RE: holdings RNS24 Jul 2019 10:21
I've just checked valirx website and they show 903.
but this is the last EHGO RNS:
London, UK., 28 June 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces that further to the announcement dated 25 June 2019 in relation to the conditional termination of the entire Subscription Agreement with the European High Growth Opportunities SF (the "Investor"), the Company has issued 121,428,571 new ordinary shares at a price of 0.175 pence per ordinary share ("Investor Shares"), as agreed between the Company and the Investor in connection with the termination of the Subscription Agreement.
The Investor Shares will rank pari passu in all respects with the existing ordinary shares of the Company. Application has been made to the London Stock Exchange for the Investor Shares to be admitted to trading on AIM. Admission of the Investor Shares is expected to occur on or around 3 July 2019 ("Admission"). In accordance with the arrangements agreed between the Company and the Investor, termination of the entire Subscription Agreement will occur upon both Admission and the Investor Shares being credited to the Investor's nominated CREST account in connection with Admission.
Following Admission, the Company's enlarged issued share capital will comprise 1,024,057,953 ordinary shares of 0.1p each with voting rights. The Company does not hold any shares in treasury. This figure of 1,024,057,953 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.